Mark Boguniewicz

机构：National Jewish Health, University of Colorado Denver · ORCID：0000-0002-1015-4439

发表论文 397 篇 · 总被引 27901 次 · h-index 82

代表论文

• A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology (2024 · Annals of Allergy Asthma & Immunology · 被引 34)
• Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis (2024 · Journal of Allergy and Clinical Immunology · 被引 30)
• Atopic Dermatitis (Eczema) Guidelines 2023: Highlights (2024 · The Journal of Allergy and Clinical Immunology In Practice · 被引 22)
• Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies (2024 · American Journal of Clinical Dermatology · 被引 18)
• Efficacy and Safety of Once‐Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild‐to‐Moderate Atopic Dermatitis ( INTEGUMENT ‐ PED ): A Phase 3 Randomized Controlled Trial (2025 · Pediatric Dermatology · 被引 17)
• Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities (2024 · Advances in Therapy · 被引 11)